The following has been clearly shown in trials using angiotensin-converting-enzyme inhibitors (ACE inhibitors) for type 1 diabetes and angiotensin-II receptor blockers (ARBs) for type 2. This evidence concerns the gene ACE and type 1 diabetes mellitus.